The cervix-ripening effect of 15-methyl-prostaglandin F2 alpha methyl ester before vacuum aspiration for termination of early pregnancy in primigravidae.
A double blind clinical trial on prostaglandin for cervix ripening prior to vacuum aspiration for termination of early pregnancy in primigravidae was carried out in 68 patients with 6-11 week's gestation. The patients were randomly treated with either 1.0 mg of 15-methyl-prostaglandin F2 alpha methyl ester vaginal suppository or a placebo suppository. A mean cervical dilation to 6.6 mm was achieved with minimal side effects in the prostaglandin group as against 4.3 mm in the placebo group. The 15-methyl-prostaglandin F2 alpha methyl ester suppository technique seems to be effective, safe and simple in ripening the cervix for termination of early pregnancy in primigravidae.
Wang
Y F
YF
Jin
Y C
YC
Wu
Y E
YE
Gu
L J
LJ
Xie
X H
XH
D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D004107:Dilatation and Curettage / Q000379:methods*; D015237:Dinoprost / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D013488:Suppositories; D014619:Vacuum Curettage / Q000379:methods*
D013488:Suppositories; C030319:prostaglandin F2alpha 15-methyl ether; D015237:Dinoprost